GLP-1 Daily: Ozempic & Wegovy News
Semaglutide Lowers Heart Pressures in Small HFpEF Trial; Lilly Drugs Come to Hims & Hers
Monday, November 9, 2026 · 6 min
A peer-reviewed 81-patient trial in Nature Medicine found semaglutide lowered heart filling pressures in obesity-related HFpEF, while Lilly and Hims & Hers announced self-pay access to Zepbound and Foundayo. Plus, Forbes on the gap between Medicare GLP-1 Bridge sign-ups and filled prescriptions.
Listen
Show notes
A peer-reviewed 81-patient trial in Nature Medicine found semaglutide lowered heart filling pressures in obesity-related HFpEF, while Lilly and Hims & Hers announced self-pay access to Zepbound and Foundayo. Plus, Forbes on the gap between Medicare GLP-1 Bridge sign-ups and filled prescriptions.
In this episode
- Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial | Nature Medicine — Nature Medicine
“The results from this trial indicate that, in patients with HFpEF and obesity, treatment with semaglutide reduced left heart filling pressures during exercise and at rest and was associated with hemodynamic HFpEF remission in over half of treated patients.”
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines — Business Wire
“Hims & Hers has never offered access to compounded copies of Lilly’s GLP-1s, and has committed not to do so in the future. Additionally, as part of the agreement, the companies have committed to protecting independent clinical decision-making, so that providers on the Hims &…”
- Medicare’s Bridge Weight Loss Program Off To Good Start, But Challenges Remain — Yahoo News
“Nevertheless, challenges lie ahead, illustrated in part by the sizable gap between the more than 1.1 million beneficiaries who've signed up for Bridge and the 700,000 or so who've successfully filled a prescription. Prior authorization hurdles, strict clinical criteria at the…”